SEC 13F Intelligence

Managers / Q2 2022 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$137M
Q2 2022
Positions
64
Filings on Record
39
2019–present window
Filed
Aug 12, 2022
original filing

Summary

Birchview Capital, LP reported $137M in U.S.-listed holdings across 64 positions for Q2 2022.

The portfolio is heavily concentrated: BMY alone accounts for 40.8% of reported value.

Compared with Q1 2022, the fund opened 1 new position and exited 4.

Portfolio Metrics

Turnover
+8.7%
vs prior filed quarter
Top-10 Concentration
+73.2%
share of reported value
Largest Position
+40.8%
Bristol Myers Squibb
New / Exited
1 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 89.9%Other: 10.1%
  • Common Stock · 89.9% · $124M
  • Other · 10.1% · $14M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
XENEXENON PHARMACEUTICALS INCNEW+10.0K10.0K+$304,000$304,000
PHRPHREESIA INCADDED+72.7K82.7K+$2M$2M
OVVOVINTIV INCADDED+50.0K84.2K+$2M$4M
PROTHENA CORP PLCADDED+60.6K102.5K+$1M$3M
BIIBBIOGEN INCSOLD OUT−10.1K0−$2M$0
AMARIN CORP PLCSOLD OUT−300.0K0−$987,000$0
VNDAVANDA PHARMACEUTICALS INCSOLD OUT−50.0K0−$566,000$0
AKBAAKEBIA THERAPEUTICS INCSOLD OUT−20.0K0−$14,000$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM40.76%$56M727.8K
2ELUTAZIYO BIOLOGICS INChistory →COM7.29%$10M1.42M
3NBIXNEUROCRINE BIOSCIENCES INChistory →COM6.04%$8M85.2K
4QDEL*QUIDELORTHO CORPhistory →COM4.33%$6M61.3K
5FHTXFOGHORN THERAPEUTICS INChistory →COM2.82%$4M284.8K
6OVVOVINTIV INChistory →COM2.71%$4M84.2K
7UTHUNITED THERAPEUTICS CORPhistory →COM2.57%$4M15.0K
8ACADACADIA PHARMACEUTICALS INChistory →COM2.56%$4M249.4K
9BIODESIX INCCOM2.13%$3M1.81M
10PROTHENA CORP PLCSHS2.03%$3M102.5K
11CLRUSDCONTINENTAL RESOURCES INChistory →COM1.84%$3M38.6K
12BDQMALBIREO PHARMA INChistory →COM1.63%$2M113.0K
13ACCELERATE DIAGNOSTICS INCCOM1.63%$2M2.25M
14BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM1.59%$2M15.0K
15PHRPHREESIA INChistory →COM1.50%$2M82.7K
16MASI*MASIMO CORPhistory →COM1.45%$2M15.3K
17ALKERMES PLCSHS1.08%$1M50.0K
18GOSSGOSSAMER BIO INCCOM0.97%$1M159.1K
19HROWHARROW HEALTH INCCOM0.95%$1M180.0K
20KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.88%$1M269.3K
21HTDCORCEPT THERAPEUTICS INCCOM0.86%$1M50.0K
22CYTKCYTOKINETICS INCCOM0.71%$982,00025.0K
23AVEO PHARMACEUTICALS INCCOM0.67%$918,000140.0K
24PXDEURPIONEER NATURAL RESOURCES COCOM0.62%$848,0003.8K
25ETRNUSDEQUITRANS MIDSTREAM CORPORATIOCOM0.62%$846,000133.1K
26INBXUSDINHIBRX INCCOM0.58%$800,00070.4K
27TSVT*2SEVENTY BIO INCCOM0.57%$790,00059.8K
28DCGODOCGO INCCOM0.57%$785,000110.0K
29SOLENO THERAPEUTICS INCCOM0.49%$680,0003.68M
30INARI MEDICAL INCCOM0.49%$680,00010.0K
31IMGNEURIMMUNOGEN INCCOM0.49%$675,000150.0K
32ARVNARVINAS INCCOM0.46%$631,00015.0K
33CFRXEURCONTRAFECT CORPCOM0.45%$614,000200.0K
34TURNING POINT THERAPEUTICS INCCOM0.44%$602,0008.0K
35CGEMCULLINAN MANAGEMENT INCCOM0.42%$578,00045.1K
36APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.39%$543,00012.0K
37CCXIEURCHEMOCENTRYX INCCOM0.36%$496,00020.0K
38NKTREURNEKTAR THERAPEUTICSCOM0.35%$486,000128.0K
39IRTCIRHYTHM TECHNOLOGIES INCCOM0.31%$432,0004.0K
40AM6AMICUS THERAPEUTICS INCCOM0.30%$408,00038.0K
41BLUEBIRD BIO INCCOM0.30%$406,00098.0K
42VTYXUSDVENTYX BIOSCIENCES INCCOM0.29%$404,00033.0K
434XC1KALVISTA PHARMACEUTICALS INCCOM0.29%$394,00040.0K
44SILKUSDSILK ROAD MEDICAL INCCOM0.26%$364,00010.0K
45XNCRXENCOR INCCOM0.25%$337,00012.3K
46XENEXENON PHARMACEUTICALS INCCOM0.22%$304,00010.0K
47PTGXPROTAGONIST THERAPEUTICS INCCOM0.22%$301,00038.0K
48KINIKSA PHARMACEUTICALS LTDCOM0.21%$291,00030.0K
49ZNTLZENTALIS PHARMACEUTICALS INCCOM0.16%$225,0008.0K
50BCRXBIOCRYST PHARMACEUTICALS INCCOM0.15%$212,00020.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.